

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/251630660>

Corrigendum to “Selective benzimidazole inhibitors of the antigen receptor-mediated NF- κ B activation pathway” [Bioorg. Med. Chem. 18 (2010) 1918–1924]

ARTICLE *in* BIOORGANIC & MEDICINAL CHEMISTRY · FEBRUARY 2011

Impact Factor: 2.79 · DOI: 10.1016/j.bmc.2010.12.019

READS

17

6 AUTHORS, INCLUDING:



Mary Macdonald

Johnson & Johnson

15 PUBLICATIONS 177 CITATIONS

SEE PROFILE



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



Corrigendum

Corrigendum to “Selective benzimidazole inhibitors of the antigen receptor-mediated NF-κB activation pathway” [Bioorg. Med. Chem. 18 (2010) 1918–1924]

Karl J. Okolotowicz^{a,*}, Ranxin Shi^{b,†}, Xueying Zheng^a, Mary MacDonald^a, John C. Reed^b, John R. Cashman^a

^a Human BioMolecular Research Institute, 5310 Eastgate Mall, San Diego, CA 92121, USA

^b Burnham Institute for Medical Research, 10901 N. Torrey Pines Rd., La Jolla, CA 92037, USA

The authors regret that there was an error in the NMR reporting for one compound in this article. The corrected compound appears below.

4.1.6.1. 2-(2-(3-Hydroxypropylamino)-5,6-dimethyl-1H-benzo[d]imidazol-1-yl)-1-(3,5-di-*tert*-butyl-4-hydroxyphenyl)ethanone (1). $R_f = 0.3$. ^1H NMR (CDCl_3 , 300 MHz) δ 1.46 (s, 18H), 1.61–1.82 (m, 2H), 2.29 (s, 6H), 3.58 (t, $J = 5.6$, 2H), 3.67 (t, $J = 5.5$, 2H), 5.13 (s, 2H), 6.84 (s, 1H), 7.23 (s, 1H), 7.89 (s, 2H). MS (ESI) calculated $\text{C}_{28}\text{H}_{39}\text{N}_3\text{O}_3$ $m/z = 465.30$, found $m/z = 466.82$ [M+H].

DOI of original article: [10.1016/j.bmc.2010.01.039](https://doi.org/10.1016/j.bmc.2010.01.039)

* Corresponding author. Tel.: +1 858 458 9305; fax: +1 858 458 9311.

E-mail address: kokolotowicz@hbri.org (K.J. Okolowicz).

† Contributed equally to the manuscript.